Skip to main content
. Author manuscript; available in PMC: 2021 Nov 1.
Published in final edited form as: J Geriatr Oncol. 2020 Mar 10;11(8):1274–1278. doi: 10.1016/j.jgo.2020.03.005

Figure 2:

Figure 2:

First-Line Treatment Patterns by Drug Class and Year

The rate of myeloma treatment in the over 80 year old population increased from 41% to 60% from 2007 to 2013. While immunomodulatory drug (IMID) use was relatively stable over that period, proteasome inhibitor use increased nearly three-fold.